Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Furosemide sodium (Frusemide Sodium) 是 Na+/K+/2Cl- (NKCC),NKCC1 和 NKCC2 共转运蛋白的有效的和具有口服活性抑制剂。Furosemide sodium 也是 GABAA 受体拮抗剂,对含 α6 受体的选择性是含 α1 受体的 100 倍。Furosemide sodium 用作利尿试剂,用于充血性心力衰竭,高血压和水肿的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 199 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 769 | 现货 |
产品描述 | Furosemide sodium (Frusemide Sodium) is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema. |
靶点活性 | NKCC:, GABAA receptor: |
体外活性 | Furosemide sodium (500 µM; 72-96 hours) significantly changes the proliferation rates in MKN45 cells (the poorly differentiated human gastric adenocarcinoma cell line). however, it has no effects on MKN28 cells (the moderately differentiated human gastric adenocarcinoma cell line). The growth rate of MKN45 cells is larger than that of MKN28 cells[4]. Furosemide sodium (10 µM, 30 µM, 100 µM; 45 min exposure)significantly decreases cation channel activity and [Ca(2+)](i) in human erythrocytes drawn from healthy individuals. Tert-butylhydroperoxide similarly enhances the non-selective cation channels activity, increases [Ca(2+)](i) and triggered cell membrane scrambling, however, the effects is significantly blunted by Furosemide sodium again[5]. |
体内活性 | Furosemide sodium (intraperitoneal injection; 100 mg/kg; single dose) is injected after kanamycin (KM) (1000 mg/kg) to creat a deaf mouse model in C57BL/6 mouse. After injection, hearing loss and cochlear hair cell damage are evaluated on day 1, day 2 and day 3, respectively. The hearing is markedly deteriorated even from the next day (Day-1 group), OHCs (outer hair cell) morphology of apical, middle and basal turns are disorganized in mice on day3[1]. |
别名 | Frusemide Sodium, Lasix |
分子量 | 352.73 |
分子式 | C12H10ClN2NaO5S |
CAS No. | 41733-55-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 135mg/mL (382.7mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.835 mL | 14.1751 mL | 28.3503 mL | 70.8757 mL |
5 mM | 0.567 mL | 2.835 mL | 5.6701 mL | 14.1751 mL | |
10 mM | 0.2835 mL | 1.4175 mL | 2.835 mL | 7.0876 mL | |
20 mM | 0.1418 mL | 0.7088 mL | 1.4175 mL | 3.5438 mL | |
50 mM | 0.0567 mL | 0.2835 mL | 0.567 mL | 1.4175 mL | |
100 mM | 0.0284 mL | 0.1418 mL | 0.2835 mL | 0.7088 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Furosemide sodium 41733-55-5 Membrane transporter/Ion channel Na-K-Cl cotransporter Frusemide Sodium Lasix Inhibitor inhibitor inhibit